Suchergebnisse - "Dudnik, Elizabeth"

PubPharm (75)

51

Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer : Findings from the Real-Life Cohort

enthalten in: Oncology research and treatment | 2019

von Bedas, A. | Peled, N. | Maimon Rabinovich, N. | +8

52

Effectiveness and safety of nivolumab in advanced non-small cell lung cancer : The real-life data

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2018

von Dudnik, E. | Moskovitz, M. | Daher, S. | +17

53

The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2018

von Laufer-Geva, S. | Rozenblum, A. | Twito, T. | +10

54

Circulating Cell-Free Tumor DNA in the Management of Double Primary Tumors

enthalten in: JCO precision oncology | 2018

von Dudnik, E. | Twito, T. | Faull, I. | +4

55

Intensity-modulated radiotherapy is a safe and effective treatment for localized malignant pleural mesothelioma

enthalten in: Thoracic cancer | 2018

von Simon, M. | Shochat, T. | Peled, N. | +6

56

Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC) : Outcomes with immune check-point inhibitors (ICPi)

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2018

von Dudnik, E. | Bshara, E. | Grubstein, A. | +10

57

Thrombosis, anticoagulation and outcomes in malignant superior vena cava syndrome

enthalten in: Journal of thrombosis and thrombolysis | 2018

von Ratzon, R. | Tamir, S. | Friehmann, T. | +11

58

Thrombosis, anticoagulation and outcomes in malignant superior vena cava syndrome

enthalten in: Journal of thrombosis and thrombolysis | 2018

von Ratzon, R. | Tamir, S. | Friehmann, T. | +11

59

Thrombosis, anticoagulation and outcomes in malignant superior vena cava syndrome

enthalten in: Journal of thrombosis and thrombolysis | 2018

von Ratzon, R. | Tamir, S. | Friehmann, T. | +11

60

BRAF Mutant Lung Cancer : Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2018

von Dudnik, E. | Peled, N. | Nechushtan, H. | +17

CommentIn: J Thorac Oncol. 2018 Aug;13(8):1055-1057. - PMID 30056857